General Biotechnology

Biotechnology in PolandI will be presenting at Bioinnovation 2014 in Gdansk, Poland on October 20-21st.

My talk will cover entrepreneurship and business development guidance from my textbook, Building Biotechnology and global competitiveness considerations from my global biotechnology ranking for Scientific American Worldview.

I look forward to meeting European and Polish biotechnology practitioners, and learning more about biotechnology in Poland.

When:

October 20-21, 2014

Where:

Gdansk Science & Technology Park

 

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Embryo and stem cell research: Views from the USA

Go to paper

ABSTRACT: Presents a study that examined the history, ethical debates and religious views regarding embryo and stem cell research in the U.S. Effect of the abortion debate on embryo research in the U.S.; Reason behind the reluctance of the federal government to fund therapeutic research; Role of the private sector in the development of embryo and stem cell research.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Mergers and acquisitions are regular events for biotechnology companies. I have often been asked if being acquired is a goal for biotechnology companies, and if it is seen as a ‘good’ or a ‘bad’ thing.

Value Creation in Biotechnology
Value Creation in Biotechnology

The outlook on merging with another company, or being acquired, is really just a matter of timing. As I describe in my textbook, Building Biotechnology, the goal of young biotechnology companies is to de-risk their technologies to the point that the value of the company exceeds the time and financial investments. For example, the value of most biotechnology companies will be lower than the inputs for the course of much of their early research. Ideally, there will be an inflection point(s) as R&D progresses where the potential of serving lucrative markets will yield a healthy valuation. At this point, a company may lean on its strong valuation to raise funds at attractive rates, or seek to sell/license technologies or seek to merge with or be acquired by a more mature firm.

This brisk illustration glosses over many of the nuances of biotechnology R&D and fund raising;  the greater point I want to make is how public companies can avoid being acquired.

When the perceived value of a company exceeds the cost to acquire that company, investors and acquirers may seek to purchase the company, to profit from the difference in the company’s value vs. its cost. While a private company (and its shareholders) may resist acquisition by simply not selling their shares, public companies do not have that luxury. Because shares in public companies can be purchased on open exchanges, it may not be possible for a public company to prevent acquisition by restricting the sale of stock.

So, what can a public company do to prevent acquisition?

On a recent visit to Carlsbad, California, I asked this very question of ISIS Pharmaceuticals CEO Stanley T. Crooke*. He had a relatively simple answer: Offer potential acquirers the technology and products they seek at a price that is lower than the cost to acquire the whole company.

Unfortunately time did not allow two important follow-up questions: Firstly, how can a CEO prevent being overruled by the board of directors (who are charged with representing the interests of shareholders) when intentionally sacrificing short-term returns for a potential long-term payout? And, secondly, what is to prevent an aggressive company from acquiring ISIS if only to prevent another licensee from doing the same and blocking the first licensee from its access to ISIS’ technologies?

*An interesting note about Stanley Crooke. He founded ISIS more than 20 years ago, and remains CEO to this day. This is in sharp contrast to most biotechnology company founders, who are replaced shortly following venture financing or IPO (When should you fire the founder)

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Patient access to innovation: Biopharmaceuticals, 4th hurdles and socioeconomic issues

Go to paper

ABSTRACT: Biopharmaceuticals and innovative therapeutic solutions offer treatments that are increasingly tailored to patient needs. Although biotechnology has produced health benefits, biopharmaceutical products require resources that governments had not planned or budgeted for in the appropriate time frame...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

I will be giving a talk on September 10th at George Washington University on two recent data analytics projects:

Firstly, I will present Scientific American Worldview, a global biotechnology ranking I developed six years ago and have managed since. The primary challenges in developing Worldview have been ensuring that the product is accessible to a general audience and ensuring that it delivers actionable guidance to countries at all levels of development.

The second project I will present is PatentStat.com, a website dedicated to increasing transparency in patent prosecution. PatentStat ranks patent attorneys and law firms in 33 technology areas, and profiles patent examiners. The primary challenges in developing PatentStat have been reducing the multi-terabyte United States patent database into a focused dataset amenable to manipulation on commodity hardware and, once again, ensuring the product is accessible to a general audience by actionable and relevant to an advanced audience.

Where:

GWU, Funger Hall, Room 103
2201 G St. NW, Washington, DC

When:

Wednesday, September 10, 2014
6:30 PM to 9:00 PM

Hope to see you there!

Drug Patent Expirations for September 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,662,271 Sep 2, 2014
BONIVA Roche ibandronate sodium 5,662,918 Sep 2, 2014
HEPSERA Gilead adefovir dipivoxil 5,663,159 Sep 2, 2014
VIGAMOX Alcon Pharms Ltd moxifloxacin hydrochloride 5,607,942*PED Sep 4, 2014
MOXEZA Alcon Pharms Ltd moxifloxacin hydrochloride 5,607,942*PED Sep 4, 2014
ALINIA Romark nitazoxanide 6,020,353 Sep 8, 2014
ALINIA Romark nitazoxanide 5,578,621 Sep 8, 2014
PROTOPIC Astellas tacrolimus 5,665,727 Sep 9, 2014
RENVELA Genzyme sevelamer carbonate 5,667,775 Sep 16, 2014
RENAGEL Genzyme sevelamer hydrochloride 5,667,775 Sep 16, 2014
ALINIA Romark nitazoxanide 6,020,353 Sep 18, 2014
EXUBERA Pfizer insulin recombinant human 6,543,448 Sep 21, 2014
ATRALIN Dow Pharm tretinoin 5,670,547 Sep 23, 2014
NAROPIN Fresenius Kabi Usa ropivacaine hydrochloride 5,670,524 Sep 23, 2014
NEORAL Novartis cyclosporine 5,985,321 Sep 26, 2014
IONSYS Incline Therap fentanyl hydrochloride 7,027,859 Sep 26, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Media coverage and biotechnology IPOs: Some Australian evidence

Go to paper

ABSTRACT: This paper analyses Australian biotechnology initial public offerings and the role of media coverage during the issue period in explaining capital raising, sentiment and underpricing. This paper finds empirical support for the hypothesis that an issuing company that receives more press coverage during the listing process leaves significantly more money on the table than those who receive less coverage, a finding consistent with the presence of sentiment effects and hot issue periods.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Transfer to Africa of the resources and rewards from biotechnology: The need for a participatory approach

Go to paper

ABSTRACT: The low adoption rate of new technologies by rural communities in developing countries in the 1970s and 1980s revealed a need for a different approach to the setting of research agendas and technology transfer. More recent programmes have shown a shift away from 'top-down' researcher-led projects, towards a 'bottom-up' participatory approach...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Drug Patent Expirations for July 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
EXALGO Mallinckrodt Inc hydromorphone hydrochloride 5,702,725 Jul 7, 2014
EXALGO Mallinckrodt Inc hydromorphone hydrochloride 5,914,131 Jul 7, 2014
AGENERASE Glaxosmithkline amprenavir 5,646,180 Jul 8, 2014
ACUTECT Cis Bio Intl Sa technetium tc-99m apcitide 5,645,815 Jul 8, 2014
INCRELEX Ipsen Inc mecasermin recombinant 5,824,642 Jul 8, 2014
AMITIZA Sucampo Pharms lubiprostone 5,284,858 Jul 14, 2014
VANIQA Skinmedica eflornithine hydrochloride 5,648,394 Jul 15, 2014
PROPULSID QUICKSOLV Janssen Pharma cisapride monohydrate 5,648,093 Jul 15, 2014
RELENZA Glaxosmithkline zanamivir 5,648,379 Jul 15, 2014
ZELAPAR Valeant Pharm Intl selegiline hydrochloride 5,648,093 Jul 15, 2014
LOESTRIN 24 FE Warner Chilcott ethinyl estradiol; norethindrone acetate 5,552,394 Jul 22, 2014
MINASTRIN 24 FE Warner Chilcott Llc ethinyl estradiol; norethindrone acetate 5,552,394 Jul 22, 2014
LO LOESTRIN FE Warner Chilcott Llc ethinyl estradiol; norethindrone acetate 5,552,394 Jul 22, 2014
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE Warner Chilcott ethinyl estradiol; norethindrone acetate 5,552,394 Jul 22, 2014
LO MINASTRIN FE Warner Chilcott ethinyl estradiol; norethindrone acetate 5,552,394 Jul 22, 2014
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE Warner Chilcott ethinyl estradiol; norethindrone 5,552,394 Jul 22, 2014
NUTROPIN DEPOT Genentech somatropin recombinant 5,656,297 Jul 25, 2014
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 6,365,581*PED Jul 27, 2014
ASMANEX HFA Merck Sharp Dohme mometasone furoate 6,057,307*PED Jul 27, 2014
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 6,949,532*PED Jul 27, 2014
DULERA Merck Sharp Dohme formoterol fumarate; mometasone furoate 5,889,015*PED Jul 27, 2014
SUMAVEL DOSEPRO Zogenix Inc sumatriptan succinate 5,891,086 Jul 27, 2014
NASONEX Merck Sharp Dohme mometasone furoate monohydrate 5,837,699*PED Jul 27, 2014
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 6,057,307*PED Jul 27, 2014
ASMANEX HFA Merck Sharp Dohme mometasone furoate 6,365,581*PED Jul 27, 2014
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 6,677,322*PED Jul 27, 2014
ASMANEX HFA Merck Sharp Dohme mometasone furoate 5,889,015*PED Jul 27, 2014
DULERA Merck Sharp Dohme formoterol fumarate; mometasone furoate 6,057,307*PED Jul 27, 2014
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 5,889,015*PED Jul 27, 2014
NASONEX Merck Sharp Dohme mometasone furoate monohydrate 6,723,713*PED Jul 27, 2014
KALETRA Abbvie lopinavir; ritonavir 5,484,801*PED Jul 28, 2014
NORVIR Abbvie ritonavir 5,484,801*PED Jul 28, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

The DNA/RNA market to 2010

Go to paper

ABSTRACT: The DNA/RNA market is currently at an early stage of development, with only two marketed products that together generated an estimated US$30m in 2004. The launch of Pfizer/Eyetech's ophthalmological aptamer Macugen (pegaptanib) is set to help power market growth to US$1.2bn by 2010. Of the 229 active DNA/RNA programmes identified by Datamonitor, oncology currently dominates the therapeutic focus, while antisense and gene therapies dominate the technological focus.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website